James Foster compensation by year
CHARLES RIVER LABORATORIES INTERNATIONAL Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $1,143,993 | $1,184,033 | $1,225,473 | $1,272,885 | $1,354,971 | $1,353,841 | $1,399,442 | $1,461,866 | $1,512,578 | $1,545,636 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Stock awards | $5,998,210 | $6,949,917 | $7,903,665 | $9,534,134 | $8,160,030 | $8,359,896 | $8,759,995 | $9,138,724 | $8,951,630 | $11,601,089 |
| Option awards | $1,511,430 | $1,754,523 | $2,014,101 | $2,374,052 | $2,058,396 | $2,062,193 | $2,179,888 | $2,294,372 | $2,275,004 | $0 |
| Non-equity incentive | $1,760,780 | $1,227,700 | $2,333,580 | $1,820,543 | $1,430,772 | $1,871,457 | $1,030,973 | $1,130,074 | $616,671 | $2,182,666 |
| Pension and deferred compensation | $135,777 | $223,247 | $16,734 | $435,171 | $194,061 | $0 | $0 | $0 | $0 | $0 |
| All other | $2,624,723 | $1,236,176 | $957,249 | $2,285,320 | $285,181 | $58,194 | $77,574 | $71,887 | $117,726 | $105,829 |
| Total | $13,174,913 | $12,575,597 | $14,450,801 | $17,722,105 | $13,483,411 | $13,705,581 | $13,447,872 | $14,096,924 | $13,473,609 | $15,435,220 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. DEF 14A filed March 31, 2026, accession 0001104659-26-037367, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filed document, accession 0001104659-26-037367. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 183,136 | $37,297,478 | — |
| RSU | 17,253 | $3,513,746 | — |
| Option | 6,011 | — | $244.41 |
| Option | 14,088 | — | $194.12 |
| Option | 18,644 | — | $208.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
21 Form 4 lines since the FY2025 proxy (filed March 31, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-22 | Sale | 10b5-1 | 24,042 | $350.00 | 31,596 |
| 2026-10-22 | Exercise or conversion | 10b5-1 | 24,042 | $244.41 | 55,638 |
| 2026-10-22 | Exercise or conversion derivative | 10b5-1 | 24,042 | $0.00 | 0 |
| 2026-08-25 | Exercise or conversion derivative | 10b5-1 | 12,429 | $0.00 | 12,429 |
| 2026-08-25 | Sale | 10b5-1 | 33,561 | $300.00 | 31,596 |
| 2026-08-25 | Exercise or conversion | 10b5-1 | 21,132 | $194.12 | 52,728 |
| 2026-08-25 | Exercise or conversion derivative | 10b5-1 | 21,132 | $0.00 | 7,044 |
| 2026-08-25 | Exercise or conversion | 10b5-1 | 12,429 | $208.44 | 65,157 |
The 8 most recent of 21 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CHARLES RIVER LABORATORIES INTERNATIONAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| James Foster · this page | Chair, President and Chief Executive Officer | $15,435,220 |
| Birgit Girshick | Corporate Executive Vice President, Chief Operating Officer | $5,898,392 |
| Joseph LaPlume | Corporate Executive Vice President, Corporate Development & Strategy | $3,513,345 |
| Victoria Creamer | Corporate Executive Vice President and Chief People Officer | $3,332,387 |
| Flavia Pease | Corporate Executive Vice President, Chief Financial Officer | $2,952,695 |
| Michael Knell | Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer | $2,107,684 |
Board service
CHARLES RIVER LABORATORIES INTERNATIONAL board · FY2021–FY2025How this board is paid
Company policy: CHARLES RIVER LABORATORIES INTERNATIONAL pays directors a $65,000 cash retainer and $255,500 in RSUs/Options. As stated in CHARLES RIVER LABORATORIES INTERNATIONAL's FY2025 proxy.
Committees
Strategic Planning and Capital Allocation
The full CHARLES RIVER LABORATORIES INTERNATIONAL compensation record
free company briefThis page is one person within CHARLES RIVER LABORATORIES INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CHARLES RIVER LABORATORIES INTERNATIONAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CHARLES RIVER LABORATORIES INTERNATIONAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CHARLES RIVER LABORATORIES INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CRL
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.